Loading...
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
PURPOSE: The Phase 3 ENDEAVOUR study evaluated revusiran, an investigational RNA interference therapeutic targeting hepatic transthyretin (TTR) production, for treating cardiomyopathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. METHODS: Patients with hATTR amyloidosis with cardi...
Saved in:
| Published in: | Cardiovasc Drugs Ther |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer US
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7242280/ https://ncbi.nlm.nih.gov/pubmed/32062791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-019-06919-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|